To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Researchers at I2BC/CEA-Joliot, in collaboration with the RPBS platform, have developed the third version of their InterEvDock server for structural modelling of protein-protein interactions. The server integrates new algorithms for exploiting sequence evolution information.
Teams from CEA-Iramis and CEA-Joliot (team "Genome transcriptional regulation /I2BC) have joined forces to develop and validate an innovative microfluidic-based system that automatizes cell culture over many generations. It enables with considerable time savings large-scale experiments to be carried out, which are essential for understanding the cellular mechanisms involved in DNA mutation events.
Researchers from BioMaps (SHFJ) and the Department of Memory and Language Neurology (Ste Anne's Hospital) studied the early clinical signs of Alzheimer's disease (AD) reported by young patients (< 62 years old) compared to those reported in classic AD of the elderly (> 65 years old). They show that these signs are misleading and often appear in the professional context.
Researchers from I2BC/CEA-Joliot in collaboration with teams from Institut Curie and IRCM/CEA-Jacob, lay the molecular basis to explain the dual role of the Mlh1-Mlh3 complex in DNA mismatch repair and, quite uniquely, in one of the key steps of genetic mixing during meiosis.
A team from SIMoS (DMTS) in collaboration with Sanofi shows that the introduction of non-natural sequences into an immunogenic peptide attenuates the immune response against this peptide, an approach that could guide the design of less immunogenic, and therefore more effective, therapeutic peptides.
Researchers at BioMaps (SHFJ) have succeeded in determining the interaction dynamics of buprenorphine, an opioid drug with a particularly complex pharmacology, with its brain receptors in vivo. To do so, they developed an original PET imaging approach based on the use of the radiolabeled molecule (11C-buprenorphine).
Researchers at the CEA-Joliot Institute (Carbon-14 labeling Laboratory), in collaboration with teams from AstraZeneca, Sanofi and Nimbe (CEA-Iramis), have developed a labeling method, based on nitrile exchange using nickel catalysis. This method is currently under study at Sanofi for the labeling of a drug candidate.
The Ginkgo team (BAOBAB / NeuroSpin), in collaboration with the Inserm iBRAIN U1253 unit (Tours), published in NeuroImage the first anatomical atlas of the human brainstem with at mesoscopic scaleresolution from extreme ultra-high field MRI. Freely available as a wiki, this atlas will be used in particular by neuroanatomists and neurosurgeons.
Research from CEA, Collège de France, CNRS and Université Paris 8 shows that humans share a universal ability to understand abstract geometric concepts. This human ability does not depend on age, culture or education, but does not exist in the non-human primates tested. PNAS has just published their results.
Researchers from NeuroSpin and CNRGH (Jacob Institute) have studied, on a genome-wide scale, the potential associations of haplotypes (set of variants located side by side on a chromosome) with the opening value of imaged brain sulci, indicator of brain aging, from the UK Biobank neuroimaging-genetics cohort.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.